BAYER AG

Daré Bioscience received a $6 million non-dilutive grant installment, bringing total funding to $37.8 million of up to $49 million committed for DARE-LARC1 contraceptive development.

RedHill Biopharma has initiated patient recruitment for a Phase 2 study evaluating opaganib plus darolutamide in men with metastatic castrate-resistant prostate cancer, sponsored by ANZUP and supported by Bayer.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

Bayer and Tsinghua University have extended their strategic research collaboration by three additional years, building on a 16-year partnership that has produced over 70 joint research projects and more than 10 publications in top international journals.

A multicenter retrospective study of 108 patients demonstrated that tislelizumab, with or without tyrosine kinase inhibitors, significantly extended recurrence-free survival in high-risk hepatocellular carcinoma patients after curative resection.

Bayer and the Broad Institute have extended their decade-long cardiovascular research collaboration by an additional five years, focusing on precision cardiology target identification and novel therapeutic approaches.

The 5th annual BIOSeedin Innovation Partnering Conference attracted over 2,000 registrants from 10 countries, facilitating 7,275 meeting requests and confirmed deals across oncology, rare diseases, and next-generation modalities.

The Phase II CONFIDENCE study demonstrated that simultaneous initiation of finerenone and empagliflozin achieved a 52% reduction in urine albumin-to-creatinine ratio (UACR) in patients with chronic kidney disease and type 2 diabetes.

Vividion Therapeutics has secured exclusive worldwide rights to develop VVD-214, the only clinical-stage covalent inhibitor of Werner helicase (WRN) currently in development globally.

Bayer has submitted marketing authorization applications for gadoquatrane, an investigational MRI contrast agent that delivers 60% lower gadolinium dosing compared to standard agents while maintaining diagnostic efficacy.